News | April 27, 2022
Syngene full-year revenue from operations up 19% to Rs. 2604 crore
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
Ind-Ra maintains a neutral outlook for healthcare in FY23
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
Key takeaways of Q3FY22 quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
Subscribe To Our Newsletter & Stay Updated
